Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,398,552 papers from all fields of science
Search
Sign In
Create Free Account
axitinib
Known as:
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
, axitinibum
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Narrower (2)
AG 013736
Inlyta
Broader (3)
Imidazoles
Indazoles
Protein Kinase Inhibitors
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Receptor Tyrosine Kinase Inhibitors [MoA]
axitinib 1 MG Oral Tablet [Inlyta]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
R. Jain
,
S. Gandhi
,
S. George
Urologic oncology
2017
Corpus ID: 28361948
2016
2016
Perspective: What next for treatment?
R. Motzer
Nature
2016
Corpus ID: 4456177
We need to focus on five main areas to make real progress in the treatment of kidney cancer, says Robert J. Motzer.
2016
2016
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer.
C. Rothermundt
,
C. Hader
,
Silke Gillessen
Annals of Oncology
2016
Corpus ID: 41330987
ABSTRACT Efficacy of anti-PD-1 antibody was demonstrated in a patient with metastatic renal cell cancer on systemic steroids for…
Expand
2015
2015
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
A. Heine
,
S. Held
,
+5 authors
P. Brossart
PLoS ONE
2015
Corpus ID: 18837476
Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of…
Expand
Highly Cited
2013
Highly Cited
2013
Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors*
Franziska Stehle
,
K. Schulz
,
+4 authors
B. Seliger
Journal of Biological Chemistry
2013
Corpus ID: 24117358
Background: Targeted therapies with tyrosine kinase inhibitors (TKIs) are used for the treatment of advanced renal cell carcinoma…
Expand
Review
2013
Review
2013
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
E. Calvo
,
A. Ravaud
,
J. Bellmunt
Cancer Treatment Reviews
2013
Corpus ID: 45860852
Review
2012
Review
2012
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
S. Oudard
,
R. Elaidi
Cancer Treatment Reviews
2012
Corpus ID: 6669948
2012
2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
M. Daimon
,
Tomoyuki Kato
,
+8 authors
T. Kato
Japanese Journal of Clinical Oncology
2012
Corpus ID: 30488057
OBJECTIVE Targeted drugs are generally associated with a lower toxicity than conventional systemic cytotoxic drugs and, thus, are…
Expand
Highly Cited
2008
Highly Cited
2008
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
J. Fruehauf
,
J. Lutzky
,
+7 authors
O. Rixe
2008
Corpus ID: 73851501
9006 Background: No treatment has extended survival in stage IV melanoma. Melanomas are highly angiogenic and metastatic, express…
Expand
2007
2007
Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial
J. Schiller
,
T. Larson
,
+7 authors
A. Olszanski
2007
Corpus ID: 74269200
7507 Background: A correlation between vascular endothelial growth factor (VEGF), microvessel density, and prognosis has been…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE